Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma

Hiroyuki Terasawa, Hideaki Kunugasa, Soichiro Ako, Mami Hirai, Hiroshi Matsushita, Daisuke Uchida, Takeshi Tomoda, Kazuyuki Matsumoto, Shigeru Horiguchi, Hironari Katou, Kazuhiro Nouso, Hiroyuki Okada

Research output: Contribution to journalArticle

Abstract

In recent years, liquid biopsy for blood and body fluid in cancer patients has attracted attention. However, there have been few reports of liquid biopsy focusing on urine of pancreatic ductal adenocarcinoma (PDAC). In 56 patients with PDAC, DNA was extracted from urine and plasma prior to treatment, and KRAS mutations were analyzed with droplet digital PCR to examine the mutation detection rate. Our study showed that KRAS mutations were found in 27 cases (48%) in urine and 27 cases (48%) in plasma. The detection rate of urine KRAS mutations varied by renal functions. The rates were 70% (14/20) and 36% (13/36) in the creatinine clearance rate (CCr) < 70 mL/min group and in the CCr ≥ 70 mL/min group, respectively (P = .024). Whereas, no influence of the CCr was observed in the detection rates of plasma KRAS mutations. The rates were 50% (10/20) and 47% (17/36) in cases with the CCr < 70 mL/min group and the CCr ≥ 70 mL/min group, respectively. Although the sample size was small, this study clearly indicated a new possibility of less invasive urine liquid biopsy in PDAC patients.

Original languageEnglish
Pages (from-to)1348-1353
Number of pages6
JournalCancer biology & therapy
Volume20
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Creatinine
Adenocarcinoma
Urine
Biopsy
Mutation
Body Fluids
Mutation Rate
Sample Size
Kidney
Polymerase Chain Reaction
DNA
Neoplasms
Therapeutics

Keywords

  • Liquid biopsy
  • pancreatic ductal adenocarcinoma
  • PDAC
  • urine

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. / Terasawa, Hiroyuki; Kunugasa, Hideaki; Ako, Soichiro; Hirai, Mami; Matsushita, Hiroshi; Uchida, Daisuke; Tomoda, Takeshi; Matsumoto, Kazuyuki; Horiguchi, Shigeru; Katou, Hironari; Nouso, Kazuhiro; Okada, Hiroyuki.

In: Cancer biology & therapy, Vol. 20, No. 10, 01.01.2019, p. 1348-1353.

Research output: Contribution to journalArticle

@article{ef20db4e66ac44e081c2b89a07899abe,
title = "Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma",
abstract = "In recent years, liquid biopsy for blood and body fluid in cancer patients has attracted attention. However, there have been few reports of liquid biopsy focusing on urine of pancreatic ductal adenocarcinoma (PDAC). In 56 patients with PDAC, DNA was extracted from urine and plasma prior to treatment, and KRAS mutations were analyzed with droplet digital PCR to examine the mutation detection rate. Our study showed that KRAS mutations were found in 27 cases (48{\%}) in urine and 27 cases (48{\%}) in plasma. The detection rate of urine KRAS mutations varied by renal functions. The rates were 70{\%} (14/20) and 36{\%} (13/36) in the creatinine clearance rate (CCr) < 70 mL/min group and in the CCr ≥ 70 mL/min group, respectively (P = .024). Whereas, no influence of the CCr was observed in the detection rates of plasma KRAS mutations. The rates were 50{\%} (10/20) and 47{\%} (17/36) in cases with the CCr < 70 mL/min group and the CCr ≥ 70 mL/min group, respectively. Although the sample size was small, this study clearly indicated a new possibility of less invasive urine liquid biopsy in PDAC patients.",
keywords = "Liquid biopsy, pancreatic ductal adenocarcinoma, PDAC, urine",
author = "Hiroyuki Terasawa and Hideaki Kunugasa and Soichiro Ako and Mami Hirai and Hiroshi Matsushita and Daisuke Uchida and Takeshi Tomoda and Kazuyuki Matsumoto and Shigeru Horiguchi and Hironari Katou and Kazuhiro Nouso and Hiroyuki Okada",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/15384047.2019.1638685",
language = "English",
volume = "20",
pages = "1348--1353",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

TY - JOUR

T1 - Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma

AU - Terasawa, Hiroyuki

AU - Kunugasa, Hideaki

AU - Ako, Soichiro

AU - Hirai, Mami

AU - Matsushita, Hiroshi

AU - Uchida, Daisuke

AU - Tomoda, Takeshi

AU - Matsumoto, Kazuyuki

AU - Horiguchi, Shigeru

AU - Katou, Hironari

AU - Nouso, Kazuhiro

AU - Okada, Hiroyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In recent years, liquid biopsy for blood and body fluid in cancer patients has attracted attention. However, there have been few reports of liquid biopsy focusing on urine of pancreatic ductal adenocarcinoma (PDAC). In 56 patients with PDAC, DNA was extracted from urine and plasma prior to treatment, and KRAS mutations were analyzed with droplet digital PCR to examine the mutation detection rate. Our study showed that KRAS mutations were found in 27 cases (48%) in urine and 27 cases (48%) in plasma. The detection rate of urine KRAS mutations varied by renal functions. The rates were 70% (14/20) and 36% (13/36) in the creatinine clearance rate (CCr) < 70 mL/min group and in the CCr ≥ 70 mL/min group, respectively (P = .024). Whereas, no influence of the CCr was observed in the detection rates of plasma KRAS mutations. The rates were 50% (10/20) and 47% (17/36) in cases with the CCr < 70 mL/min group and the CCr ≥ 70 mL/min group, respectively. Although the sample size was small, this study clearly indicated a new possibility of less invasive urine liquid biopsy in PDAC patients.

AB - In recent years, liquid biopsy for blood and body fluid in cancer patients has attracted attention. However, there have been few reports of liquid biopsy focusing on urine of pancreatic ductal adenocarcinoma (PDAC). In 56 patients with PDAC, DNA was extracted from urine and plasma prior to treatment, and KRAS mutations were analyzed with droplet digital PCR to examine the mutation detection rate. Our study showed that KRAS mutations were found in 27 cases (48%) in urine and 27 cases (48%) in plasma. The detection rate of urine KRAS mutations varied by renal functions. The rates were 70% (14/20) and 36% (13/36) in the creatinine clearance rate (CCr) < 70 mL/min group and in the CCr ≥ 70 mL/min group, respectively (P = .024). Whereas, no influence of the CCr was observed in the detection rates of plasma KRAS mutations. The rates were 50% (10/20) and 47% (17/36) in cases with the CCr < 70 mL/min group and the CCr ≥ 70 mL/min group, respectively. Although the sample size was small, this study clearly indicated a new possibility of less invasive urine liquid biopsy in PDAC patients.

KW - Liquid biopsy

KW - pancreatic ductal adenocarcinoma

KW - PDAC

KW - urine

UR - http://www.scopus.com/inward/record.url?scp=85072152160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072152160&partnerID=8YFLogxK

U2 - 10.1080/15384047.2019.1638685

DO - 10.1080/15384047.2019.1638685

M3 - Article

VL - 20

SP - 1348

EP - 1353

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -